가격실적기술 분석펀더멘탈 Cerus Corp, 4.96, 5.04, 4.88, +0.02, +0.40%, 2.70M, 08/02 MannKind Corp, 1.450, 1.520, 1.440, -0.080, -5.23%, 2.12M, 08/02. Find the latest MannKind Corporation (MNKD) stock quote, history, news and other vital information to help you with your stock trading and investing. MannKind develops cutting-edge therapeutic products and technologies to change lives for the better. Summary ToggleMannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD. 09/19/19. WESTLAKE Stock analysis for MannKind Corp (MNKD:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Summary ToggleMannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD. 09/19/19. WESTLAKE
가격실적기술 분석펀더멘탈 Cerus Corp, 4.96, 5.04, 4.88, +0.02, +0.40%, 2.70M, 08/02 MannKind Corp, 1.450, 1.520, 1.440, -0.080, -5.23%, 2.12M, 08/02. Find the latest MannKind Corporation (MNKD) stock quote, history, news and other vital information to help you with your stock trading and investing. MannKind develops cutting-edge therapeutic products and technologies to change lives for the better. Summary ToggleMannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD. 09/19/19. WESTLAKE Stock analysis for MannKind Corp (MNKD:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
가격실적기술 분석펀더멘탈 Cerus Corp, 4.96, 5.04, 4.88, +0.02, +0.40%, 2.70M, 08/02 MannKind Corp, 1.450, 1.520, 1.440, -0.080, -5.23%, 2.12M, 08/02.
가격실적기술 분석펀더멘탈 Cerus Corp, 4.96, 5.04, 4.88, +0.02, +0.40%, 2.70M, 08/02 MannKind Corp, 1.450, 1.520, 1.440, -0.080, -5.23%, 2.12M, 08/02. Find the latest MannKind Corporation (MNKD) stock quote, history, news and other vital information to help you with your stock trading and investing. MannKind develops cutting-edge therapeutic products and technologies to change lives for the better. Summary ToggleMannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD. 09/19/19. WESTLAKE Stock analysis for MannKind Corp (MNKD:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Stock analysis for MannKind Corp (MNKD:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
가격실적기술 분석펀더멘탈 Cerus Corp, 4.96, 5.04, 4.88, +0.02, +0.40%, 2.70M, 08/02 MannKind Corp, 1.450, 1.520, 1.440, -0.080, -5.23%, 2.12M, 08/02. Find the latest MannKind Corporation (MNKD) stock quote, history, news and other vital information to help you with your stock trading and investing. MannKind develops cutting-edge therapeutic products and technologies to change lives for the better. Summary ToggleMannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD. 09/19/19. WESTLAKE
Find the latest MannKind Corporation (MNKD) stock quote, history, news and other vital information to help you with your stock trading and investing.
가격실적기술 분석펀더멘탈 Cerus Corp, 4.96, 5.04, 4.88, +0.02, +0.40%, 2.70M, 08/02 MannKind Corp, 1.450, 1.520, 1.440, -0.080, -5.23%, 2.12M, 08/02. Find the latest MannKind Corporation (MNKD) stock quote, history, news and other vital information to help you with your stock trading and investing. MannKind develops cutting-edge therapeutic products and technologies to change lives for the better. Summary ToggleMannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD. 09/19/19. WESTLAKE Stock analysis for MannKind Corp (MNKD:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.